About Iovance Biotherapeutics (NASDAQ:IOVA)
Iovance Biotherapeutics, Inc., formerly Lion Biotechnologies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. The Company's lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients' tumors, for the treatment of metastatic melanoma. As of December 31, 2016, it had an on-going Phase II clinical trial of its lead product candidate, LN-144, TIL for the treatment of metastatic melanoma. The Company is developing LN-145 to treat cervical and head and neck cancers. It is collaborating with the National Cancer Institute to evaluate unmodified TIL in other solid tumor indications, such as ocular melanoma, bladder, breast and lung cancer. It is collaborating with the NCI to evaluate TIL in combination with the checkpoint inhibitor, Keytruda.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IOVA
CUSIPN/A
Phone650-260-7120
Debt
Debt-to-Equity RatioN/A
Current Ratio15.10%
Quick Ratio15.10%
Price-To-Earnings
Trailing P/E Ratio-10.28
Forward P/E Ratio-11.60
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.71 per share
Price / Book8.48
Profitability
EPS (Most Recent Fiscal Year)($1.41)
Net Income$-92,060,000.00
Net MarginsN/A
Return on Equity-62.42%
Return on Assets-59.14%
Miscellaneous
Employees63
Outstanding Shares89,450,000
Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions
What is Iovance Biotherapeutics' stock symbol?
Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."
How were Iovance Biotherapeutics' earnings last quarter?
Iovance Biotherapeutics Inc (NASDAQ:IOVA) issued its quarterly earnings data on Monday, March, 12th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.04. View Iovance Biotherapeutics' Earnings History.
What price target have analysts set for IOVA?
9 analysts have issued 1-year price targets for Iovance Biotherapeutics' stock. Their forecasts range from $13.00 to $31.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $20.9375 in the next year. View Analyst Ratings for Iovance Biotherapeutics.
What are Wall Street analysts saying about Iovance Biotherapeutics stock?
Here are some recent quotes from research analysts about Iovance Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies Inc., is based in SAN CARLOS, United States. " (1/20/2018)
- 2. Cowen Inc analysts commented, "IOVA reported that the first patient in LN-145’s Phase II cervical cancer study has been." (8/16/2017)
- 3. HC Wainwright analysts commented, "We project that one or more of these patients who achieved early PRs could transform to CRs with more follow up time as the infused TILs continue to act." (6/7/2017)
Who are some of Iovance Biotherapeutics' key competitors?
Some companies that are related to Iovance Biotherapeutics include CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Sangamo Therapeutics (SGMO), Repligen (RGEN), Acceleron Pharma (XLRN), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), REGENXBIO (RGNX), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP) and Acorda Therapeutics (ACOR).
Who are Iovance Biotherapeutics' key executives?
Iovance Biotherapeutics' management team includes the folowing people:
- Wayne Rothbaum, Interim Chairman of the Board
- Maria Fardis Ph.D., President, Chief Executive Officer
- Gregory T. Schiffman, Chief Financial Officer
- James G. Bender Ph.D., Vice President
- Iain D Dukes, Director
- , Bio & Compensation -
- Ryan D. Maynard, Director
- Sanford J. Hillsberg J.D., Independent Director
- Merrill A. McPeak USAF, Independent Director
- Jay Venkatesan M.D., Independent Director
Has Iovance Biotherapeutics been receiving favorable news coverage?
Press coverage about IOVA stock has been trending somewhat negative on Monday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Iovance Biotherapeutics earned a media sentiment score of -0.06 on Accern's scale. They also gave news stories about the biotechnology company an impact score of 44.77 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
How do I buy shares of Iovance Biotherapeutics?
Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iovance Biotherapeutics' stock price today?
One share of IOVA stock can currently be purchased for approximately $14.50.
How big of a company is Iovance Biotherapeutics?
Iovance Biotherapeutics has a market capitalization of $1.33 billion. The biotechnology company earns $-92,060,000.00 in net income (profit) each year or ($1.41) on an earnings per share basis. Iovance Biotherapeutics employs 63 workers across the globe.
How can I contact Iovance Biotherapeutics?
Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]
MarketBeat Community Rating for Iovance Biotherapeutics (IOVA)
MarketBeat's community ratings are surveys of what our community members think about Iovance Biotherapeutics and other stocks. Vote "Outperform" if you believe IOVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IOVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Iovance Biotherapeutics in the last 12 months. Their average twelve-month price target is $20.9375, suggesting that the stock has a possible upside of 44.40%. The high price target for IOVA is $31.00 and the low price target for IOVA is $13.00. There are currently 9 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 2.89 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $20.9375 | $20.9375 | $15.3125 | $14.9286 |
| Price Target Upside: | 44.40% upside | 9.33% upside | 43.11% upside | 124.49% upside |
Iovance Biotherapeutics (NASDAQ:IOVA) Consensus Price Target History
Iovance Biotherapeutics (NASDAQ:IOVA) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Iovance Biotherapeutics (NASDAQ:IOVA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Iovance Biotherapeutics (NASDAQ IOVA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 13.20%
Institutional Ownership Percentage: 64.46%
Iovance Biotherapeutics (NASDAQ IOVA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/25/2016 | Sanford Hillsberg | Director | Sell | 54,000 | $8.95 | $483,300.00 | |  |
| 8/22/2016 | Sanford Hillsberg | Director | Sell | 54,000 | $9.11 | $491,940.00 | | |
| 9/8/2015 | Sanford Hillsberg | Director | Sell | 32,500 | $6.99 | $227,175.00 | | |
| 5/6/2015 | Sanford Hillsberg | Director | Sell | 50,000 | $10.00 | $500,000.00 | | |
| 11/5/2013 | Manish Singh | CEO | Buy | 125,000 | $2.00 | $250,000.00 | | |
(Data available from 1/1/2013 forward)
Iovance Biotherapeutics (NASDAQ IOVA) News Headlines
| Source: |
|
Iovance Biotherapeutics (NASDAQ:IOVA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Iovance Biotherapeutics (NASDAQ:IOVA) Income Statement, Balance Sheet and Cash Flow Statement
Iovance Biotherapeutics (NASDAQ IOVA) Stock Chart for Monday, April, 23, 2018
Loading chart…
